<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014569</url>
  </required_header>
  <id_info>
    <org_study_id>RMC018718ctil</org_study_id>
    <nct_id>NCT04014569</nct_id>
  </id_info>
  <brief_title>Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational &amp; Proof of Concept Study</brief_title>
  <official_title>Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational &amp; Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DreaMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MDI (Multiple Daily Injections) plus SMBG |(Self Monitoring Blood Glucose) Advisor (MPSA)
      is a software product that is designed to assist in insulin dosage decision making for
      subjects with T1DM using multiple daily injection and SMBG.

      The study will focus on the development, validation and eventually testing of the MPSA
      algorithm use. The major objective of the project is to develop an algorithm that will be
      able to optimize treatment plan parameters of MDI patients who use SMBG as glucose monitoring
      method. The clinical study has two segments. Segment A is an observational study needed for
      the development of the algorithm (this segment was already completed at the time of the
      registration) and Segment B is a proof of concept interventional study to validate the
      algorithm's Safety and Efficacy.

      Up to 20 patients using MDI and SMBG or Flash Glucose Monitoring (FGM) without using glucose
      trends will be enrolled to this proof of concept study. The study will evaluate the algorithm
      use for a period of 11 weeks. Post screening, patients will undergo a two weeks run-in period
      while using MDI and SMBG or FGM (patients that do not use FGM will be provided with blinded
      Libre Flash to be used during the run-in period and 2 weeks prior to arriving to end of study
      visit). Then, patients will undergo insulin treatment plan changes every week for 7 weeks. At
      the first 3 weeks insulin dose adjustments will be done for basal insulin dose only, week 4
      will be without changes, and in the next 3 weeks the carbohydrate ratio will be amended. No
      recommendations will be given during the last two weeks of the study. These two weeks will be
      used for data analysis. Each recommendation of the Advisor will be approved by a physician
      before implementation. Glucose outcomes will be evaluated comparing the two weeks run-in
      period to the last two weeks of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of sensor glucose readings within range of 70-180 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of sensor glucose readings below 54 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Hypoglycemia events</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic Ketoacidosis events</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings below 70 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings below 50mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings above 180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings above 250mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of unexplained hyperglycemic events</measure>
    <time_frame>Final visit (day42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area above the curve of 180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area above the curve &gt;180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve of 70mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve &lt;70mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean sensor blood glucose</measure>
    <time_frame>Final visit (day42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose variability measured by SD (standard deviation)</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in settings per patient</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in setting per iteration</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of physician override advisor recommendations</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Multiple Daily Injections</condition>
  <arm_group>
    <arm_group_label>MPSA Algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin dosing will be adjusted using the MPSA algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MPSA Algorithm</intervention_name>
    <description>Insulin dosing will be adjusted using the MPSA Algorithm</description>
    <arm_group_label>MPSA Algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented T1D for at least 1 year prior to study enrolment

          -  Subjects aged ≥ 14 years and up to 30 years

          -  A1c at inclusion ≥ 7 % and ≤ 10%

          -  Using MDI of Basal/bolus therapy - basal insulin either Glargine/Lantus or Tregludec
             insulin and bolus short acting insulin analogs either aspart/Novorapid or
             Lispro/Humalog

          -  Using SMBG or flash glucose monitoring (FGM/Libre) without using glucose trends

          -  BMI SDS - below the 97th percentile for age

          -  Subjects willing to follow study instructions

        Exclusion Criteria:

          -  An episode of diabetic keto-acidosis within the month prior to study entry and/or
             severe hypoglycemia resulting in seizure or loss of consciousness in the month prior
             to enrolment

          -  Concomitant diseases/ treatment that influence metabolic control or any significant
             diseases /conditions including psychiatric disorders and substance abuse that in the
             opinion of the investigator is likely to affect the subject's ability to complete the
             study or compromise patient's safety

          -  Participation in any other interventional study

          -  Known or suspected allergy to trial products

          -  Female subject who is pregnant or planning to become pregnant within the planned study
             duration

          -  Subject needs to travel by air during the study duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moshe Phillip, Prof.</last_name>
    <phone>972-3-9253282</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Hamou, MSc</last_name>
    <phone>972-3-9253282</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schnider children medical center</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Phillip, Professor</last_name>
      <phone>972-3-9253778</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Shlomit Shalitin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liat De Vries, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Oron, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravital Nimri, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Tenenbaum, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Bello, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noa Shffer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Nevo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sari Karpel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

